Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMark A. SchroederBarnes-Jewish Hospital

Discussion

Loading...

Member takes

Implication

Prospective trial finds M+G mobilization improves CD34+ yields in newly diagnosed multiple myeloma patients, suggesting effective premedication reduces adverse effects.

Key Points

  • Mobilization led to 100% of patients collecting 2×106 CD34+ cells/kg in two leukocytapheresis procedures.
  • Peak PB hematopoietic stem cell mobilization was 62.5 CD34+ cells/μl, compared to historical control's 116 CD34+ cells/μl.
  • Prospective trial assessed efficacy of motixafortide and G-CSF in mobilization following quad induction therapy.
  • Enhanced premedication reduced adverse effect rates significantly compared to historical rates with standard premeds.

Cite This Study

Mark A. Schroeder (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db25https://doi.org/10.1182/blood-2025-5957
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease2025 · 2 citations
  2. 2Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers2025
  3. 3Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study2025 · 2 citations
  4. 4Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial2025
  5. 5Impact of pomalidomide-containing induction chemotherapy on hematopoietic stem cell mobilization in multiple myeloma: A retrospective cohort study2025